Influence of the SCN1A, SCN2A and ABCB1 polymorphisms on therapy with oxcarbazepine for epilepsy

Effects of SCN1A, SCN2A and ABCB1 genetic polymorphisms on plasma oxcarbazepine concentrations and pharmacoresistance in Chinese Han patients with epilepsy

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR-OCH-14004528

Enrollment

Unknown

Registered

2014-04-13

Start date

2014-04-14

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

epilepsy

Interventions

pharmacoresistant:oxcarbazepine

drug responsiveness:oxcarbazepine

Eligibility

Sex/Gender

All

Age

No minimum to 90 Years

Inclusion criteria

Inclusion criteria: Chinese Han patients with epilepsy, clinical diagnosis more than six months

Exclusion criteria

Exclusion criteria: With severe organic diseases such as hypertension, unstable heart disease, blood disease, liver and kidney dysfunction; suffering from any Progressive diseases such as cancer; suffering from any organic brain or central nervous system diseases.

Design outcomes

Primary

Measure	Time frame
plasma drug concentration;	—

Countries

China

Contacts

Public ContactFang Shu

Xiangya Hospital, Central South University

fangshuvic@163.com+86 15111235160

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 18, 2026